Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a China-based biopharmaceutical company, has announced a licensing agreement with an undisclosed company due to commercial sensitivity and trade secret considerations.
Exclusive Licensing Rights for Greater China
According to the agreement, Junshi Bio will secure exclusive licensing rights and sublicensing rights to two dual-targeted fusion proteins across Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan. Additionally, the two companies will share global rights equally for one of the products in the agreement.
Development Stages and Financial Terms
Both products under the agreement are intended to treat malignant tumors. One product has already entered Phase I trials overseas, with a clinical filing under review in China, while the other remains in the pre-clinical stage.
Junshi Bio will make an upfront payment of USD 1.5 million to the licensor and is committed to paying up to RMB 740 million (USD 102 million) in milestone payments, contingent upon the product’s research and development and sales performance. The agreement also includes single-digit net sales royalties based on the sales status of one of the products in Greater China. Furthermore, if the licensor sublicenses the rights obtained from Junshi Bio to a third party, Junshi Bio may receive up to 20% of the sub-license revenue or USD 200 million, whichever is lower.-Fineline Info & Tech
Leave a Reply